MX9805810A - Agentes anticoagulantes, utiles en el tratamiento de trombosis. - Google Patents

Agentes anticoagulantes, utiles en el tratamiento de trombosis.

Info

Publication number
MX9805810A
MX9805810A MX9805810A MX9805810A MX9805810A MX 9805810 A MX9805810 A MX 9805810A MX 9805810 A MX9805810 A MX 9805810A MX 9805810 A MX9805810 A MX 9805810A MX 9805810 A MX9805810 A MX 9805810A
Authority
MX
Mexico
Prior art keywords
thrombosis
treatment
agents useful
anticoagulant agents
anticoagulant
Prior art date
Application number
MX9805810A
Other languages
English (en)
Inventor
Michael Neal Blackburn
William Robert Church
Giora Zeev Feuerstein
Mitchell Stuart Gross
Andrew John Nichols
Eduardo Agustin Padlan
Arunbhai Haribhai Patel
Daniel Robert Sylvester
Original Assignee
Smithkline Beecham Corp
Univ Vermont And State
Agricultural College
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp, Univ Vermont And State, Agricultural College filed Critical Smithkline Beecham Corp
Publication of MX9805810A publication Critical patent/MX9805810A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Están descritos anticuerpos monoclonales dirigidos contra los factores de coagulacion, y su uso en la inhibicion de la trombosis.
MX9805810A 1996-01-17 1998-07-17 Agentes anticoagulantes, utiles en el tratamiento de trombosis. MX9805810A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US1010896P 1996-01-17 1996-01-17
US2911996P 1996-10-24 1996-10-24

Publications (1)

Publication Number Publication Date
MX9805810A true MX9805810A (es) 1998-11-30

Family

ID=26680794

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9805810A MX9805810A (es) 1996-01-17 1998-07-17 Agentes anticoagulantes, utiles en el tratamiento de trombosis.

Country Status (26)

Country Link
US (5) US6005091A (es)
EP (2) EP1832297A1 (es)
JP (2) JP2000503210A (es)
KR (1) KR100553629B1 (es)
CN (1) CN1213312A (es)
AR (1) AR005658A1 (es)
AT (1) ATE330630T1 (es)
AU (1) AU706397B2 (es)
BR (1) BR9707049A (es)
CZ (1) CZ299452B6 (es)
DE (1) DE69736197T2 (es)
DK (1) DK1007089T3 (es)
ES (1) ES2267131T3 (es)
HK (1) HK1029513A1 (es)
HU (1) HU225903B1 (es)
ID (1) ID17156A (es)
IL (1) IL125380A0 (es)
MA (1) MA24512A1 (es)
MX (1) MX9805810A (es)
NO (1) NO983284L (es)
NZ (2) NZ501215A (es)
PL (1) PL187274B1 (es)
PT (1) PT1007089E (es)
SI (1) SI1007089T1 (es)
TR (1) TR199801390T2 (es)
WO (1) WO1997026010A1 (es)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA24512A1 (fr) * 1996-01-17 1998-12-31 Univ Vermont And State Agrienl Procede pour la preparation d'agents anticoagulants utiles dans le traitement de la thrombose
US20040038898A1 (en) * 1996-05-16 2004-02-26 The Trustees Of Columbia University Method for inhibiting thrombosis in a patient whose blood is subjected to extracorporeal circulation
US6610293B1 (en) 1997-06-16 2003-08-26 The Henry M. Jackson Foundation For The Advancement Of Military Medicine Opsonic and protective monoclonal and chimeric antibodies specific for lipoteichoic acid of gram positive bacteria
WO1999001476A1 (en) * 1997-07-03 1999-01-14 Smithkline Beecham Corporation CRYSTAL STRUCTURES OF ANTI-FACTOR IX Fab FRAGMENTS AND METHODS OF USE FOR PEPTIDOMIMETIC DESIGN
DE19802139C1 (de) 1998-01-22 1999-09-23 Centeon Pharma Gmbh Monoklonaler Antikörper spezifisch für aktivierten Gerinnungsfaktor VII und seine Verwendung
EP1095143B1 (en) * 1998-05-08 2008-08-20 Stichting Sanquin Bloedvoorziening Inhibitor for diagnosis and treatment of haemophilia a patients
US7250494B2 (en) * 1998-06-15 2007-07-31 Biosynexus Incorporated Opsonic monoclonal and chimeric antibodies specific for lipoteichoic acid of Gram positive bacteria
WO2000007626A1 (en) * 1998-08-07 2000-02-17 Smithkline Beecham Corporation Use of anti-coagulation factor antibodies as long-lasting protective agents
ES2177316T3 (es) 1998-08-28 2002-12-01 Genentech Inc Anticuerpos humanos antifacotores ix/ixa.
US6818749B1 (en) 1998-10-31 2004-11-16 The United States Of America As Represented By The Department Of Health And Human Services Variants of humanized anti carcinoma monoclonal antibody cc49
CA2348698C (en) * 1998-10-31 2012-01-03 Syed V. S. Kashmiri Variants of humanized anti-carcinoma monoclonal antibody cc49
US7829085B2 (en) 1999-07-14 2010-11-09 Life Sciences Research Partners Vzw Methods of treating hemostasis disorders using antibodies binding the C1 domain of factor VIII
US7067313B1 (en) 1999-07-14 2006-06-27 D. Collen Research Foundation Ligands for use in therapeutic compositions for the treatment of hemostasis disorders
DK1194528T3 (da) * 1999-07-14 2007-07-09 D Collen Res Foundation Vzw Monoklonalt antistof mod faktor VII, hvilket antistof selv ved forekomst i molært overskud kun delvist inaktiverer faktor VII, samt fremgangsmåde til produktion af et sådant antistof
AT411997B (de) 1999-09-14 2004-08-26 Baxter Ag Faktor ix/faktor ixa aktivierende antikörper und antikörper-derivate
US6316259B1 (en) * 2000-01-21 2001-11-13 Isis Pharmaceuticals, Inc. Antisense inhibition of glycogen synthase kinase 3 alpha expression
IL152831A0 (en) * 2000-05-15 2003-06-24 Smithkline Beecham Corp Antithrombotic agents
AU2001296305B2 (en) * 2000-09-26 2007-12-06 Duke University RNA aptamers and methods for identifying the same
ATE468136T1 (de) 2001-01-11 2010-06-15 D Collen Res Foundation Vzw Verfahren und pharmazeutische zusammensetzung zur vorbeugung und/oder behandlung des syndroms der systemischen entzündlichen reaktion
CA2441228A1 (en) * 2001-03-23 2002-10-03 Aphton Corporation Combination treatment of pancreatic cancer
US20090191232A1 (en) * 2001-05-04 2009-07-30 Gevas Philip C Combination therapy for the treatment of tumors
EP1396539B1 (en) * 2001-06-12 2008-11-26 Juridical Foundation, The Chemo-Sero-Therapeutic Research Institute Human-type anti-blood coagulation factor viii antibody
US20030021786A1 (en) * 2001-07-09 2003-01-30 Gevas Philip C. Treatment and prevention of cancerous and pre-cancerous conditions of the liver, lung and esophagus
WO2003013423A2 (en) * 2001-08-05 2003-02-20 Gvg, Inc. Antithrombotic agent
US20040052779A1 (en) * 2001-12-21 2004-03-18 Stinson Jeffrey R. Opsonic monoclonal and chimeric antibodies specific for lipoteichoic acid of Gram positive bacteria
WO2004003155A2 (en) 2002-06-28 2004-01-08 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Humanized anti-tag-72 cc49 for diagnosis and therapy of human tumors
US6928528B1 (en) 2002-10-07 2005-08-09 Advanced Micro Devices, Inc. Guaranteed data synchronization
WO2004088326A2 (en) * 2003-03-28 2004-10-14 Aphton Corporation Gastrin hormone immunoassays
JP4422430B2 (ja) 2003-05-14 2010-02-24 帝國製薬株式会社 エストロゲン及び／又はプロゲストゲン含有外用貼付剤
CA2535489C (en) 2003-08-14 2014-09-30 D. Collen Research Foundation Vzw Antibodies against factor viii with modified glycosylation in the variable region
US7589181B2 (en) 2003-08-29 2009-09-15 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Minimally immunogenic variants of SDR-grafted humanized antibody CC49 and their use
US7297336B2 (en) 2003-09-12 2007-11-20 Baxter International Inc. Factor IXa specific antibodies displaying factor VIIIa like activity
WO2005035753A1 (ja) * 2003-10-10 2005-04-21 Chugai Seiyaku Kabushiki Kaisha 機能蛋白質を代替する二重特異性抗体
AU2003271186A1 (en) * 2003-10-14 2005-04-27 Chugai Seiyaku Kabushiki Kaisha Double specific antibodies substituting for functional protein
CA2561405C (en) * 2004-03-29 2014-01-21 Receptor Biologix, Inc. Monoclonal antibodies to gastrin hormone
JP2008513536A (ja) 2004-09-22 2008-05-01 レセプター バイオロジックス インコーポレイテッド プロガストリンに対するモノクローナル抗体
ES2592271T3 (es) 2005-03-31 2016-11-29 Chugai Seiyaku Kabushiki Kaisha Métodos de producción de polipéptidos mediante la regulación de la asociación de los polipéptidos
JP5624276B2 (ja) 2006-03-31 2014-11-12 中外製薬株式会社 抗体の血中動態を制御する方法
CN105177091A (zh) 2006-03-31 2015-12-23 中外制药株式会社 用于纯化双特异性抗体的抗体修饰方法
WO2008067056A2 (en) * 2006-10-16 2008-06-05 Novelmed Therapeutics, Inc. Method of inhibiting coagulation with human anti-factor va antibodies and use thereof
RU2475500C2 (ru) 2007-09-13 2013-02-20 Деленекс Терапьютикс Аг ГУМАНИЗИРОВАННЫЕ АНТИТЕЛА К β-АМИЛОИДНОМУ ПЕПТИДУ
EP2185592B1 (en) * 2007-09-13 2013-01-23 University Of Zurich Prorektorat Forschung Monoclonal amyloid beta (abeta)-specific antibody and uses thereof
EP4368721A2 (en) 2007-09-26 2024-05-15 Chugai Seiyaku Kabushiki Kaisha Method of modifying isoelectric point of antibody via amino acid substitution in cdr
US8187591B2 (en) * 2007-10-11 2012-05-29 The Regents Of The University Of California Methods of treating coagulopathy
ES2702365T3 (es) * 2008-06-19 2019-02-28 Prothix Bv Uso de anticuerpos antifactor XI para la prevención o el tratamiento de la formación de trombos
TWI452136B (zh) 2010-11-17 2014-09-11 中外製藥股份有限公司 A multiple specific antigen-binding molecule that replaces the function of Factor VIII in blood coagulation
WO2014100740A1 (en) 2012-12-21 2014-06-26 Seattle Genetics, Inc. Anti-ntb-a antibodies and related compositions and methods
WO2014160088A2 (en) * 2013-03-14 2014-10-02 Rhode Island Hospital, A Lifespan-Partner Treating hepatitis b virus infections
SG11201602261VA (en) 2013-09-27 2016-04-28 Chugai Pharmaceutical Co Ltd Method for producing polypeptide heteromultimer
DK3177642T3 (da) 2014-08-07 2022-02-21 Novartis Ag Angiopoietin-lignende 4-antistoffer og fremgangsmåder til anvendelse deraf
TW201613977A (en) 2014-08-07 2016-04-16 Novartis Ag Angiopoetin-like 4 (ANGPTL4) antibodies and methods of use
TWI701435B (zh) 2014-09-26 2020-08-11 日商中外製藥股份有限公司 測定ｆｖｉｉｉ的反應性之方法
TWI700300B (zh) 2014-09-26 2020-08-01 日商中外製藥股份有限公司 中和具有第ｖｉｉｉ凝血因子（ｆｖｉｉｉ）機能替代活性的物質之抗體
MA40764A (fr) 2014-09-26 2017-08-01 Chugai Pharmaceutical Co Ltd Agent thérapeutique induisant une cytotoxicité
US11142587B2 (en) 2015-04-01 2021-10-12 Chugai Seiyaku Kabushiki Kaisha Method for producing polypeptide hetero-oligomer
JOP20200312A1 (ar) 2015-06-26 2017-06-16 Novartis Ag الأجسام المضادة للعامل xi وطرق الاستخدام
AU2016381992B2 (en) 2015-12-28 2024-01-04 Chugai Seiyaku Kabushiki Kaisha Method for promoting efficiency of purification of Fc region-containing polypeptide
US10053515B2 (en) * 2016-01-22 2018-08-21 Merck Sharp & Dohme Corp. Anti-coagulation factor XI antibodies
TW201802121A (zh) 2016-05-25 2018-01-16 諾華公司 抗因子XI/XIa抗體之逆轉結合劑及其用途
KR102218714B1 (ko) 2016-06-14 2021-02-24 머크 샤프 앤드 돔 코포레이션 항응고 인자 xi 항체
MA46200A (fr) 2016-09-06 2019-07-17 Chugai Pharmaceutical Co Ltd Procédés d'utilisation d'un anticorps bispécifique qui reconnaît le facteur de coagulation ix et/ou le facteur de coagulation ix activé et le facteur de coagulation x et/ou le facteur de coagulation x activé
WO2018116255A1 (en) 2016-12-23 2018-06-28 Novartis Ag Factor xi antibodies and methods of use
JP7110199B2 (ja) * 2016-12-23 2022-08-01 ノバルティス アーゲー 抗第ＸＩ／ＸＩａ因子抗体による処置法
WO2018232230A1 (en) 2017-06-15 2018-12-20 Cancer Advances Inc. Compositions and methods for inducing humoral and cellular immunities against tumors and cancer
GB201709970D0 (en) * 2017-06-22 2017-08-09 Kymab Ltd Bispecific antigen-binding molecules
CN111108202A (zh) 2017-09-29 2020-05-05 中外制药株式会社 具有凝血因子viii(fviii)辅因子功能替代活性的多特异性抗原结合分子及含有所述分子作为活性成分的药物制剂
JP2022515770A (ja) 2018-12-21 2022-02-22 カイマブ・リミテッド 共通の軽鎖を有するＦＩＸａ×ＦＸ二重特異性抗体

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3909799A1 (de) * 1989-03-24 1990-09-27 Behringwerke Ag Monoklonale antikoerper (mak) gegen tumorassoziierte antigene, ihre herstellung und verwendung
GB8928874D0 (en) * 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
CA2049655C (en) * 1990-09-17 1996-11-12 Akio Odawara Pharmaceutical composition for inhibiting platelet aggregation
WO1993009804A1 (en) * 1991-11-18 1993-05-27 The Scripps Research Institute Serine protease derived-polypeptides and anti-peptide antibodies, systems and therapeutic methods for inhibiting coagulation
US5383928A (en) * 1992-06-10 1995-01-24 Emory University Stent sheath for local drug delivery
ATE197590T1 (de) * 1992-08-27 2000-12-15 Sanquin Bloedvoorziening Antikoerper spezifisch fur ein haemostatisches protein; seine verwendung zur isolation von intaktem protein; haemostatische zusammensetzungen ohne proteolytische spaltprodukte des proteins
US5397581A (en) * 1993-02-05 1995-03-14 Lerman; Russell E. Means for continuous confectionery coating of edible centers
MA24512A1 (fr) * 1996-01-17 1998-12-31 Univ Vermont And State Agrienl Procede pour la preparation d'agents anticoagulants utiles dans le traitement de la thrombose
US20070190059A1 (en) * 1996-01-17 2007-08-16 Smithkline Beecham Corporation Antithrombotic agents

Also Published As

Publication number Publication date
KR19990077329A (ko) 1999-10-25
NO983284L (no) 1998-09-16
DK1007089T3 (da) 2006-10-09
JP2007325602A (ja) 2007-12-20
PT1007089E (pt) 2006-11-30
EP1832297A1 (en) 2007-09-12
ATE330630T1 (de) 2006-07-15
DE69736197D1 (de) 2006-08-03
AU706397B2 (en) 1999-06-17
PL187274B1 (pl) 2004-06-30
HK1029513A1 (en) 2001-04-06
CZ299452B6 (cs) 2008-07-30
SI1007089T1 (sl) 2006-12-31
NZ501215A (en) 2001-04-27
ID17156A (id) 1997-12-04
US20070003553A1 (en) 2007-01-04
IL125380A0 (en) 1999-03-12
EP1007089A4 (en) 2003-04-16
EP1007089A1 (en) 2000-06-14
MA24512A1 (fr) 1998-12-31
DE69736197T2 (de) 2007-06-21
JP2000503210A (ja) 2000-03-21
WO1997026010A1 (en) 1997-07-24
TR199801390T2 (xx) 1998-12-21
CN1213312A (zh) 1999-04-07
EP1007089B1 (en) 2006-06-21
HUP9900396A2 (hu) 1999-05-28
ES2267131T3 (es) 2007-03-01
AU1830897A (en) 1997-08-11
US6005091A (en) 1999-12-21
NZ331014A (en) 2000-01-28
CZ222598A3 (cs) 2000-01-12
KR100553629B1 (ko) 2006-10-04
BR9707049A (pt) 2000-10-24
US20020146411A1 (en) 2002-10-10
NO983284D0 (no) 1998-07-16
US20070224198A1 (en) 2007-09-27
HU225903B1 (en) 2007-12-28
PL327929A1 (en) 1999-01-04
AR005658A1 (es) 1999-07-14
US6391299B1 (en) 2002-05-21
HUP9900396A3 (en) 2001-10-29

Similar Documents

Publication Publication Date Title
MX9805810A (es) Agentes anticoagulantes, utiles en el tratamiento de trombosis.
MX9709915A (es) Heterociclos de peptidilo y composiciones que los contienen, utiles en el tratamiento de trastornos relacionados con trombina, y uso de los mismos.
CY2006007I2 (el) Χρηση αναστολεων cgmp-φωσφοδιεστερασης στην αγωγη της ανικανοτητας
MX9707570A (es) Utilizacion de agonistas de alta1l para el tratamiento de la incontinencia urinaria.
GB9506926D0 (en) Cystine-siicone copolymers and their use for treating keratin substrates
PL336788A1 (en) Probucol monoesters in treating circulatory system and inflammatory diseases
DE69703649D1 (de) Behandlung von deagglomerierten teilchen mit plasmaaktivierter spezies
ZA966707B (en) Absorbent article having improved waist region dryness and method of manufacture.
DK1039912T3 (da) Angiostatiske midler og præparater til behandling af GLC1A-glaukom
EP0939640A4 (en) IMPROVEMENTS IN POLYMERIC CHEMOTHERAPY COMPOSITIONS AND THERAPEUTIC METHODS USING THE SAME
EP1156820A4 (en) VASCULAR ENDOTHELIAL GROWTH FACTOR-2
DE69738045D1 (de) Verwendung von cetrorelix zur behandlung von benigne prostatahypertrophie und prostatakrebs
AU5886796A (en) Peptidyl heterocycles useful in the treatment of thrombin re lateddisorders
FR2715976B1 (fr) Rivets-clous et procédés de mise en Óoeuvre de ceux-ci.
BG102797A (en) The carboznhydrase inhibitor application for the treatment of the maculate oedema
BR9612283A (pt) Composição para o tratamento de manchas em peças de roupa e métodos de tratamento
DE69626816D1 (de) Verwendung von selegilin zur behandlung von gehörverlust bei säugetieren
ATE251462T1 (de) Verfahren zur behandlung von narbengewebe
TR199800575T1 (en) Kemokin �-8'in k�sa formlar�.
DE59710935D1 (de) Verfahren zum gleichmässigen und dauerhaften Verteilen von Peroxiden in Polyethylen
IL116164A0 (en) Proteins having fibrinolytic and thrombin-inhibiting properties
PT751775E (pt) Derivados de mercaptoacetilamida hipocolesterolemicos, antiateroscleroticos e hipotrigliceridemicos
DE69737570D1 (de) Agentien zur präsymptomatischen Detektion, Prävention und Behandlung von Brustkrebs in Menschen
ZA97347B (en) Anticoagulant agents useful in treatment of thrombosis
GB9723824D0 (en) Cytostatic agents

Legal Events

Date Code Title Description
FG Grant or registration
MM Annulment or lapse due to non-payment of fees